{"id":596,"date":"2022-11-15T13:20:33","date_gmt":"2022-11-15T13:20:33","guid":{"rendered":"https:\/\/iuvantium.com\/?page_id=596"},"modified":"2025-09-17T08:24:42","modified_gmt":"2025-09-17T08:24:42","slug":"team","status":"publish","type":"page","link":"https:\/\/iuvantium.com\/?page_id=596","title":{"rendered":"Team"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

our TEAM<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dr. Bj\u00f6rn Schimm\u00f6ller
<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

co-founder & CEO<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Bj\u00f6rn took his childhood enthusiasm and joy for building new things\u00a0from the ground up\u00a0<\/span>with Lego\u00ae into the chemistry classroom and later to university, where he studied Process Engineering at Karlsruhe Institute for Technology, Germany. During his diploma thesis at <\/span>ETH Z\u00fcrich, Switzerland, his love for research only grew and he extended his stay to<\/span>\u00a0earn a PhD in Material Science in Prof. Sotiris Pratsinis’ group, where he was part of a world-class inorganic chemistry laboratory and was fortunate to receive life-changing mentorship.<\/span><\/p>

After completing his PhD, Bj\u00f6rn sought to solve real-world problems by applying science. At Cabot Corporation in the USA, he gained extensive experience in nanomaterial R&D, developing new technology platforms and products. Later, by transitioning into a commercial role, he led a high tech >$30M revenue functional materials business segment. Ultimately his work took him to Oxford, UK where he was leading a global R&D team, supporting building a functional materials business from scratch. It was there that he met his co-founder Jon.<\/span><\/p>

Fascinated by the intersection of inorganic materials and their myriad applications to influence and make people’s lives better, Bj\u00f6rn’s entrepreneurial mindset and passion for people has found an outlet at iuvantium<\/span>. Here he<\/span>\u00a0is responsible for staying focused on the company’s vision, by developing and executing the business strategy while ensuring that we stay true to our “why”.<\/span><\/p>

To recharge, Bj\u00f6rn spends time with his wife and\u00a0<\/span>two sons exploring the outdoors, collecting art,\u00a0<\/span>finding serenity in his garden with focus on carnivorous plants and cooking memorable meals.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dr. Reinaldo Acevedo Grogues<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Head of Formulation<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
Rey is vaccinologist and formulation scientist with over two decades of experience on vaccine research and development. His work has been focused on the rational design of adjuvant formulations and delivery systems. During his time at the Cuban Finlay Institute, he developed and commercialized vaccines for Cubans and citizens of other countries. He led projects on novel nano vesicle and microparticle formulations targeting enteric pathogens, TB, pertussis and Neisseria among others. Furthermore, his research interests include mucosal and alternatives routes of immunization as well as the development of immune therapeutics for the treatment of cancer, addictions, allergies and metabolic diseases.<\/div>
\u00a0<\/div>
Triggered by the experience during the pandemic and capitalizing on his long-time connections in the UK, Dr Acevedo started on a new professional and personal chapter relocating to Oxford taking on a position at the University of Oxford. There, at The Jenner Institute, he contributed to the development of an antimicrobial resistance vaccine against\u00a0Neisseria gonorrhoeae<\/i>.<\/div>
\u00a0<\/div>
He later joined the local\u00a0bio<\/span>tech Evox Therapeutics, where he worked on the formulation of exosomes for gene drug delivery and rare disease targeting. More recently, he joined Micropore Technologies where lead a team dedicated to developing a novel micro-mixing technology for lipid nanoparticle formulations. Throughout his career, Dr. Acevedo has also served as a consultant and subject matter expert on vaccines for both national and international groups, such as the Global Meningococcal Initiative.<\/div>
\u00a0<\/div>
At iuvantium<\/span> he now puts his wealth of experience and know-how to use as Head of Vaccines and Formulation, responsible for our vaccine development pipeline and supporting our commercial partners in utilizing iuvantium’s platform technology in the best possible way.<\/div>
\u00a0<\/div>
In his free time, he enjoys<\/div>

exploring and discovering different places in UK as well as salsa dancing.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dr. Kalle S\u00f6derstr\u00f6m<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Head of Therapeutics<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Kalle is a creative and strategic biotech executive with more than three decades of experience leading innovative R&D programs in academia and industry across Europe and the US.<\/p>

He has held senior roles at leading organizations including Novo Nordisk, Entelos Inc., GammaDelta Therapeutics, DragonFly Therapeutics, and TCypherBio, where he successfully advanced programs toward novel therapies for autoimmune diseases and cancer.<\/p>

His academic journey spans the Karolinska Institute, Oxford University, and Stanford University, where he mentored PhD students and led high-impact research that resulted in numerous publications and multiple patents. Kalle\u2019s expertise centers on autoimmune diseases, translational immunology, T and NK cell biology, antibody therapeutics, and therapeutic vaccine development.<\/p>

At iuvantium<\/span>, he is focused on developing next-generation immunomodulatory therapies with the potential to transform the treatment of cancer and chronic inflammatory diseases. Passionate about bridging frontline scientific discoveries with patient-centered innovation, Kalle is dedicated to translating research into meaningful therapies that improve lives.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Robert Campbell<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

ML Scientist<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Robert is a PhD candidate at Oxford University, where he works on translating longevity therapies from mice to humans using genomic data.<\/p>

He holds a MSc in health data analytics and machine learning from Imperial College London. His thesis work with the AstraZeneca Oncology Data Science Team developed a novel graph attention network mechanism for identifying biomarkers in single cell RNA-seq data.<\/p>

Robert applies his expertise in bioinformatics and data science to extend iuvantium\u2019s statistical and machine learning models of immunobiology to new data modalities, and improve the targeting of iuvantium\u2019s rationally designed immunomodulator compounds.<\/p>

Outside of professional life, he has an amateur interest in non-infectious disease epidemiology, African history, and sports science.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"Ben\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Ben Griffin<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

ML Scientist<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

our ADVISORY BOARD<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Prof Adam Finn<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Adam Finn is Professor of Paediatrics at the University of Bristol and Honorary Consultant Paediatrician at Bristol Royal Hospital for Children.<\/span><\/p>

His research mostly relates to clinical vaccine development and in particular the immunological mechanisms that control transmission of infections between humans and consequent indirect population-wide impact of immunisation programmes.<\/span><\/p>

He formerly served on immunisation technical advisory groups for WHO and the UK government and acts as consultant to a number of academic and commercial groups developing vaccines. He frequently undertakes public communication work about vaccines and was often visible in the media during the COVID19 pandemic.\u00a0<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Mary Porter<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mary brings a strategic focus to intellectual property law matters, a focus annealed over time in close partnership with her inventors and business clients. As iuvantium<\/span> AB member, Mary is not providing legal advice and supports the leadership team purely from a strategic perspective.<\/p>

Her IP law practice has been international in scope and has encompassed the acquisition, protection, enforcement and monetization of technology, patent, trademark and other intellectual property assets, dispute resolution, and extensive transactional counseling.<\/p>

She is currently Partner at the IP law firm Finch & Maloney in the US. Mary began her career as a trial attorney before commencing in-house practice in the field of intellectual property. She served as intellectual property counsel to several international corporations, most recently retiring from the position of Chief Intellectual Property Counsel, Cabot Corporation. Before entering the practice of law, Mary worked as a scientist at The R.T. French Company, worked for a brief, but sweet, time at the Hershey Foods R&D laboratory and taught as an adjunct professor at Rochester Institute of Technology.<\/p>

Mary\u2019s IP law experience spans a range of technical fields, notably high temperature materials, chemistry, polymers, food ingredients, adhesives, abrasive tools and materials, mechanical devices, chemical processes and engineering and downstream applications for chemicals and materials.<\/p>

Mary has a JD degree from Villanova Law School, is admitted to practice law in the State of New York and the Commonwealth of Massachusetts and is registered to practice before the United States Patent and Trademark Office. She holds a B.S. degree in Food Science from The Pennsylvania State University and a M.S. degree in Food Science, Biochemistry minor, from Oregon State University. She has a certificate in Mediation from the Program on Negotiation at Harvard Law School.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Matt Stanton<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Matt has over 20 years\u2019 marketing experience primarily across pharmaceutical and biotechnology sectors spanning both corporate and entrepreneurial fields.<\/p>

Matt\u2019s professional experience spans both Bayer and Boehringer-Ingelheim, being involved in Global Marketing roles and as the Brand Lead responsible with market development partner Genentech for Alteplase (rt-PA), the groundbreaking treatment for acute stroke.<\/p>

Matt subsequently founded and exited two different medical consultancy & communications companies (7.4 Ltd & Fortis Pharma Ltd) and has delivered various consultancy services to many of the world\u2019s leading Life-Science Organisations, as well as start-ups within FMCG, pharmaceutical and biotechnology sectors.<\/p>

His expertise lies in conceptualizing marketing strategies, refining positioning and messaging, identifying innovative customer revenue streams, and rigorously assessing business models. This is achieved by evaluating internal capabilities and analysing the external competitive environment using wargaming methodology.<\/p>

Matt has also experience in the technology sector providing evidence-based intelligence and publications around new technologies and digital transformation.\u00a0He recently co-authored a book \u2018Maximising Value with Automation and Digital Transformation: A Realist\u2019s Guide\u2019<\/em>\u00a0advocating for a robust digital platform as the foundation for AI success.<\/p>

Outside the business sphere, Matt is a Trustee for Raleigh UK Alumni Society, which works with Raleigh International, helping to create young leaders through life-enhancing journeys and transformational international experiences.<\/p>

Matt holds an International MBA from NIMBAS, Graduate School of Management, Utrecht, Netherlands.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Dr Robert Burns<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Robert is a Board Director of Targovax and has been CEO of three companies active in research and development of antibodies (Celldex, Affitech, and 4-Antibody AG). Previously, he has been Chairman of Haemostatix, up until the successful divestment to Ergomed. Robert has previously held leading positions in commercial operations and business development at Ludwig Cancer Research, Oxford Glycosciences, British Biotechnology, Applied bioTechnology, and Corning Incorporated. Robert holds a PhD in chemistry from the University of Birmingham.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Nicholas Maishman<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Nick\u00a0has\u00a0over thirty-five years of commercial manufacturing, operations and quality management, and leadership experience. He has served as Site Head, General Manager, VP,\u00a0and COO roles within pharmaceutical, biotech, vaccine and CDMO companies, such as GlaxoSmithKline, Pfizer, Valneva, Alexion, \u00a0Recipharm and ViroCell Biologics. Nick has worked across the globe including in the UK, Ireland, France, Greece, Austria,\u00a0and USA.\u00a0<\/p>

Nick also has significant experience leading\u00a0the\u00a0construction and start-up of new manufacturing sites, securing regulatory approval for CT and commercial GMP manufacturing, including among others for complex biologics such as monoclonal antibodies and vaccines. His regulatory experience includes new product submissions to FDA and EMA and hosting site inspections from FDA, MHRA, European and International regulatory authorities.\u00a0\u00a0<\/p>

Nick was a key member of the start-up site leadership team at Pfizer, Grange Castle, a significant investment in vaccine and antibody manufacturing in Ireland. He also led the construction and start-up of the Alexion site in Dublin that manufactures products for ultra-rare diseases. Nick was Vice Principle of manufacturing for the vaccine company Valenva, where he also led the construction of a new facility for their Covid-19 vaccine.\u00a0<\/p>

Nick\u2019s most recent roles were as Chief Operating Officer at ViroCell Biologics,\u00a0an innovative CDMO that designs and manufactures viral vectors, and Interim Chief Scientific and Operations Officer for Alliance Pharmaceuticals, a\u00a0consumer\u00a0health business with international operations.\u00a0Nick has a BSc from Imperial College, London,\u00a0and an MBA from the University of Warwick Business School.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Gamal Rezk<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Gamal Rezk, an industry veteran with over 30 years of experience in the pharmaceuticals and vaccines sectors, brings unparalleled expertise and strategic leadership to Iuvantium as an advisory board member. With a distinguished career that includes serving as the Vice President Global Vaccines Commercial Leader at GSK, Gamal has a proven track record of driving innovation and delivering results in diverse global markets.<\/p>

Gamal’s journey began with a passion for science and a vision to enhance public health. He earned a degree in Pharmaceutical Sciences from Alexandria University in Egypt and an MBA in Marketing from Southeastern University in Washington, D.C., USA. His career at GSK saw him rise from key roles in the Gulf region to leading the Vaccines business for the Middle East and Africa, and eventually overseeing commercial strategies for international markets including Latin America and Asia-Pacific.<\/p>

As the former VP & Head of Vaccines for Emerging Markets at GSK, Gamal was instrumental in launching critical vaccines and forging partnerships with governments and supranational organizations to expand vaccine access in over 100 countries. His strategic foresight and leadership have been pivotal in advancing new vaccine pipelines and improving patient outcomes globally.<\/p>

Gamal leverages his extensive background to support the strategic direction of Iuvantium, positioning the company at the forefront of medical innovation and offering investors a strategic advantage in the rapidly evolving field of immunotherapy.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Prof Maggie Dallman OBE<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Maggie has over 30 yeas of immunology experience and has been an entrepeneur herself, being co-founder of a successful biotech start-up in the late 1990s. Throught his experience and learning she became determined to enable young entrepeneurs, especially female ones via the “WE Innovate” program, to start their own companies, either as spin-out from Imperial College London or on their own.<\/p>

She joined Imperial College in 1994 as a lecturer in the Department of Biology, coming from the University of Oxford where she had held a Nuffield Medical Research Foundation Junior Research Fellowship followed by an MRC Senior Research Fellowship. At Imperial College she became Reader in Immunoregulation in 1996 and Professor of Immunology in 1999. Since 2001 Maggie has held a variety of senior positions at Imperial College including Head Section Immunology and Infection, Campus Dean and Deputy Principal for the Faculty of Natural Sciences, becoming Dean of the Faculty in 2008. Maggie was made Associate-Provost (Academic Partnerships) in January 2015, and took up her most recent role as Vice-President (International) in February 2018.<\/p>

Maggie is well known for her work to improve the public understanding of science and technology, especially among those from underserved backgrounds. She is passionate about giving people from all walks of life the opportunity to reach their potential, believing that education is central in achieving this goal.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Simon Gunson<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Simon is looking back at a >30 year career in the pharmaceutical industry and is an experienced operations executive in the pharma industry having served as VP of R&D Operations, New Product Develpment and Site Director for Glaxo-Smith-Kline and most recently SCAPA Healthcare. Simon brings extensive knowledge in technical project management, operations and manufacturing strategies, and has developed business cases for innovation projects. He spent 1 year in China as Head China Category R&D for GSK and supported global teams in many roles during his tenure with GSK.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Prof Dermot O'Hare<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Professor Dermot O’Hare is a Professor of Organometallic and Materials Chemistry at Oxford, Director of the industrially funded SCG – Oxford Centre of Excellence, and MPLS Associate Head for Industrial Liaison and Innovation.<\/p>

Dermot was born in Newry, Co. Down and studied at Balliol College, Oxford for his BSc and D. Phil under the direction of Professor M.L.H Green. He was a visiting research fellow at CR&D E.I. du Pont de Nemours in Delaware, and returned to Oxford with a permanent University position and Tutorial Fellowship at Balliol College, and later a University Professorship.<\/p>

In 2020 he became Senior Research Fellow at Balliol and Professor of Organometallic and Materials Chemistry. He has been honoured by the Instit\u00fct de France, Acad\u00e9mie des Sciences, the Royal Society of Chemistry (Ludwig Mond Prize, Corday Morgan Medal, Sir Edward Frankland Prize) and by the Exxon European Chemical and Engineering Prize.<\/p>

Dermot leads a large, multi-disciplinary research team working across the broad areas of catalysis, nanomaterials, polymers and the green economy, working towards finding solutions to global issues relating to energy, zero carbon and the circular economy. In 2019 he won the Royal Society of Chemistry\u2019s Tilden Medal for outstanding research in the chemical sciences.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

our ALUMNI<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Emeritus Prof. Jon Austyn<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

scientific co-founder \/ retired<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Jon\u2019s early dream of becoming an academic was grounded in his desire to create something impactful, so others would benefit after he was gone. He became fascinated by immunology as an Oxford undergraduate and was further inspired by his greatest mentors Siamon Gordon and Ralph Steinman, during his doctoral and postdoctoral studies.<\/p>

Jon then made his career in the field, and spent much of his time trying to realize his dream amongst the spires of Oxford, It also took him to living in which took him to New York and Sydney, and, for shorter periods, in HongKong and Xiamen, China. Over the last ~40 years, Jon has embraced his passion for conducting blue-skies research, coordinating large-scale international research networks, and inspiring the next generation of immunologists as an educator.<\/p>

Jon\u2019s desire to translate his ground-breaking research into real-life applications, and to explore every option to do exactly that, finally culminated in co-founding iuvantium<\/span> to realise his dream of bringing his discovery to patients worldwide.<\/p>

After leading the immunology strategy at iuvantium<\/span> for the past 2 1\/2 years, he retired from the company for personal reasons.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

our TEAM Dr. Bj\u00f6rn Schimm\u00f6ller co-founder & CEO Bj\u00f6rn took his childhood enthusiasm and joy for building new things\u00a0from the ground up\u00a0with Lego\u00ae into the chemistry classroom and later to university, where he studied Process Engineering at Karlsruhe Institute for Technology, Germany. During his diploma thesis at ETH Z\u00fcrich, Switzerland, his love for research only […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_theme","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_themeisle_gutenberg_block_has_review":false,"footnotes":""},"class_list":["post-596","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/iuvantium.com\/index.php?rest_route=\/wp\/v2\/pages\/596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/iuvantium.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/iuvantium.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/iuvantium.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/iuvantium.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=596"}],"version-history":[{"count":340,"href":"https:\/\/iuvantium.com\/index.php?rest_route=\/wp\/v2\/pages\/596\/revisions"}],"predecessor-version":[{"id":1506,"href":"https:\/\/iuvantium.com\/index.php?rest_route=\/wp\/v2\/pages\/596\/revisions\/1506"}],"wp:attachment":[{"href":"https:\/\/iuvantium.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}